Hongliang Biopharmaceutical Technology

Hongliang Biopharmaceutical Technology is a clinical-stage biotechnology company based in Shanghai, China, focused on the development of innovative nanomedicines and nucleic acid-based therapies. The company's lead candidate, HLN601, is a liposomal anticancer drug that has entered Phase 1 clinical trials for the treatment of advanced solid tumors, including pancreatic, breast, and colorectal cancers. Hongliang leverages advanced drug delivery technologies, such as liposomal and hydrogel-based systems, to improve the therapeutic index and targeting of small molecules and oligonucleotides. The company maintains a strategic research partnership with the Shanghai Institute of Materia Medica (SIMM) and has received investment from entities associated with Baidu.